期刊文献+

埃索美拉唑钠的合成 被引量:6

Synthesis of esomeprazole sodium
原文传递
导出
摘要 目的制备埃索美拉唑钠。方法以4-甲氧基-3,5-二甲基-2-羟甲基吡啶为原料,经氯化后与5-甲氧基-2-巯基苯并咪唑反应合成奥美拉唑硫醚物,奥美拉唑硫醚物在以(1S,2S)-(-)-1,2-环己二胺-D-酒石酸盐为手性配体、环烷酸钴为催化剂、过氧化钠为氧化剂的条件下进行不对称氧化合成高光学纯度埃索美拉唑钠。结果与结论目标化合物的结构经IR、1H-NMR、13C-NMR和MS确证。该法操作简便,收率较高(45%),产品光学纯度≥99%,含量≥98%,适于工业化生产。 Esomeprazole is the first optical isomer proton pump inhibitor, and its sodium salt is applied to the patients who are in need of PPI but not capable of oral dosing. At present, there are three methods to synthesize esomeprazole such as omeprazole racemic resolution, omeprazole sulfide complexes asymmetric cataly tic oxidation and biochemical oxidation. However, the omeprazole racemic resolution is limited industrially due to its high cost and low yield. The aim of this study is to propose a modified asymmetric oxidation meth- od to prepare esomeprazole for industrialized production. Compared with the traditional method, this new method has three advantages. Firstly, the( 1S, 2S)-( -)-1,2-diaminocyclohexane D-tartrate was used as chiral ligands, which avoids the addition of organic alkali in the traditional route. Secondly, cobalt naphthenate was applied as the catalyst to solve the problem of water-contacting over traditional titanium catalyst. Lastly, sodium peroxide is not only the oxidant to lower the cost of asymmetric oxidizing the omeprazole sulfide compounds but also the source of sodium for no more addition of other sodium source.
出处 《中国药物化学杂志》 CAS CSCD 2013年第4期286-288,共3页 Chinese Journal of Medicinal Chemistry
关键词 不对称氧化 过氧化钠 埃索美拉唑钠 asymmetric oxidation sodium peroxide esomeprazole sodium
  • 相关文献

参考文献13

二级参考文献99

共引文献168

同被引文献29

  • 1戴立言,王井明,陈英奇,金旭虎.奥美拉唑的合成新工艺研究[J].浙江大学学报(工学版),2004,38(3):333-336. 被引量:10
  • 2于志卿,王美玲,王洪欣.注射用埃索美拉唑钠[J].齐鲁药事,2005,24(12):758-758. 被引量:12
  • 3Cotton H,Elebring T,Larsson M,et al.Asymmetric synthesis of esomeprazole[J].Tetrahedron:Asymmetry,2000,11(18):3819-3825.
  • 4Andersson T,Weidolf L.Stereoselective disposition of proton pump inhibitors[J].Clinical Drug Investigation,2008,28(5):263-279.
  • 5Suzuki M,Suzuki H,Hibi T.Proton pump inhibitors and gastritis[J].Journal of Clinical Biochemistry and Nutrition,2008,42(2):71-75.
  • 6Pai V,Pai N.Recent advances in chirally pure proton pump inhibitors[J].Journal of the Indian Medical Association,2007,105(8):469-474.
  • 7Szabo S,Vincze A.Growth factors in ulcer healing:Lessons from recent studies[J].Journal of Physiology Paris,2000,94(1):77-81.
  • 8Kanazawa H,Okada A,Higake M,et al.Stereospecific analysis of omeprazole in human plasma as a probe for CYP2Cl9 phenotype[J].Journal Pharmaceutical and Biomedical Analysis,2003,30(6):1817-1824.
  • 9Ha T H,Kim W J,Oh H S,et al.Method of preparing esomeprazole and salts thereof:WO,2007013743[P].2007-02-01.
  • 10Kasibhatla S R,Hong K,Biamonte M A,et al.Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity[J].Journal of Medicinal Chemistry,2007,50(12):2767-2778.

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部